Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of Lifirafenib (BGB-283) and PD-0325901 Combination in Patients with Advanced Solid Tumors

Trial Profile

A Phase 1b Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of Lifirafenib (BGB-283) and PD-0325901 Combination in Patients with Advanced Solid Tumors

Planning
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2018

At a glance

  • Drugs Lifirafenib (Primary) ; PD 325901 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors BeiGene
  • Most Recent Events

    • 17 Sep 2018 According to a BeiGene media release, all costs of the clinical studies and governance responsibilities to be shared equally among both companies.SpringWorks Therapeutics will also oversee fixed-dose formulation work as part of the collaboration.
    • 17 Sep 2018 New trial record
    • 05 Sep 2018 According to a BeiGene media release, BeiGene and SpringWorks Therapeutics have entered into a global clinical collaboration agreement to evaluate BGB-283 and PD-0325901 combination in this phase 1b trial.Under the terms of the agreement, BeiGene will be responsible for administering this trial which is expected to commence during the first quarter of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top